Beginning
Stelis Biopharma started as a subsidiary of Strides Pharma Science Limited (Strides). The business was re-branded as Stelis Biopharma to reflect a new focus as a fully integrated biopharmaceutical company.
Significant investments were made in the same year for setting up state-of-the-art process development laboratories to serve many modalities.
Investments in Process Development
With strategic investments in diverse biosimilar programs along with a decisive go-to-market approach, an attractive pipeline of biosimilar products was created. This business has now been carved out from Stelis to focus as a pure-play biopharmaceutical CDMO.
Investments in Industry-leading Infrastructure
Construction started for an integrated 200,000 square feet commercial bio-manufacturing facility for both drug substance and drug product in the North Bangalore facility. Set-up cGMP scale-up facility in South Bangalore facility 1, in technology partnership with Merck Life Sciences.
Steady Execution
A multi-platform and multi-product DS microbial facility was commissioned and qualified for commercial manufacturing.
A global biopharmaceutical CDMO with a
complete and integrated end-to-end offering
Stelis Biopharma is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), with a complete and integrated end-to-end offering. World-class process development and manufacturing infrastructure for both drug substance (mammalian and microbial-based therapeutic proteins and viral vectors) and drug product (lyophilized vials, liquid vials, pre-filled syringes, cartridges and devices). Our three state-of-the-art facilities are staffed by highly talented professionals. As the most agile CDMO in the industry, Stelis Biopharma is a trusted CDMO partner of choice.
Beginning
Stelis Biopharma started as a subsidiary of Strides Pharma Science Limited (Strides). The business was re-branded as Stelis Biopharma to reflect a new focus as a fully integrated biopharmaceutical company.
Significant investments were made in the same year for setting up state-of-the-art process development laboratories to serve many modalities.
Investments in Process Development
With strategic investments in diverse biosimilar programs along with a decisive go-to-market approach, an attractive pipeline of biosimilar products was created. This business has now been carved out from Stelis to focus as a pure-play biopharmaceutical CDMO.
Investments in Industry-leading Infrastructure
Construction started for an integrated 200,000 square feet commercial bio-manufacturing facility for both drug substance and drug product in the North Bangalore facility. Set-up cGMP scale-up facility in South Bangalore facility 1, in technology partnership with Merck Life Sciences.
Steady Execution
A multi-platform and multi-product DS microbial facility was commissioned and qualified for commercial manufacturing.
A global biopharmaceutical CDMO with a complete and integrated end-to-end offering
Stelis Biopharma is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), with a complete and integrated end-to-end offering. World-class process development and manufacturing infrastructure for both drug substance (mammalian and microbial-based therapeutic proteins and viral vectors) and drug product (lyophilized vials, liquid vials, pre-filled syringes, cartridges and devices). Our three state-of-the-art facilities are staffed by highly talented professionals. As the most agile CDMO in the industry, Stelis Biopharma is a trusted CDMO partner of choice.